REGENERON PHARMACEUTICALS, INC. - COMMON STOCK (REGN)

Historical Holders from Q1 2014 to Q4 2025

Type / Class
Equity / COMMON STOCK
Symbol
REGN on Nasdaq
Shares outstanding
104,986,330
Price per share
$771.87
All holders as of 30 Sep 2025
Q3 2025
Total 13F shares
86,922,112
Total reported value
$48,893,674,176
% of total 13F portfolios
0.03%
Share change
-2,265,719
Value change
-$1,217,117,620
Number of holders
1,225
Price from insider filings
$771.87
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of REGENERON PHARMACEUTICALS, INC. - COMMON STOCK (REGN) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
JPMORGAN CHASE & CO 4.4% -14% $2,729,989,170 -$462,704,633 4,742,611 -14% JPMORGAN CHASE & CO. 30 May 2025
FMR LLC 3.2% -55% $1,933,864,996 -$2,779,837,001 3,359,563 -59% FMR LLC 30 Jun 2025
As of 30 Sep 2025, REGENERON PHARMACEUTICALS, INC. - COMMON STOCK (REGN) has 1,225 institutional shareholders filing 13F forms. They hold 86,922,112 shares. of 104,986,330 outstanding shares (83%) .

Top 25 institutional shareholders own 54% of the company.

Filer Ownership Nb Shares Share Change % Portfolio % Holdings Value
VANGUARD GROUP INC 8.6% 9,048,269 -4% 0.08% $5,087,570,211
BlackRock, Inc. 8.4% 8,837,174 -4.7% 0.09% $4,968,878,140
STATE STREET CORP 4.5% 4,691,223 -2.9% 0.09% $2,637,733,956
Dodge & Cox 4.3% 4,550,845 +19% 1.4% $2,558,803,618
JPMORGAN CHASE & CO 3.9% 4,072,326 +3.4% 0.15% $2,289,760,415
GEODE CAPITAL MANAGEMENT, LLC 2.4% 2,535,898 +2.9% 0.09% $1,419,627,369
FRANKLIN RESOURCES INC 2.3% 2,453,143 +6% 0.35% $1,379,328,713
Capital World Investors 1.9% 1,998,366 +1.6% 0.15% $1,123,608,855
LOOMIS SAYLES & CO L P 1.9% 1,979,453 +2% 1.3% $1,112,987,056
FMR LLC 1.8% 1,935,835 -42% 0.06% $1,088,462,214
Invesco Ltd. 1.4% 1,484,473 +38% 0.13% $834,674,573
MORGAN STANLEY 1.4% 1,450,972 +13% 0.05% $815,840,196
Nuveen, LLC 1.1% 1,175,277 +40% 0.17% $660,822,999
BANK OF AMERICA CORP /DE/ 1.1% 1,153,933 -5.4% 0.05% $648,821,756
NORTHERN TRUST CORP 0.94% 984,792 +2.7% 0.07% $553,718,997
GOLDMAN SACHS GROUP INC 0.91% 952,839 +20% 0.08% $535,752,949
TWO SIGMA ADVISERS, LP 0.88% 926,200 -1.3% 1% $520,774,474
Capital International Investors 0.83% 876,564 -72% 0.08% $492,851,584
D. E. Shaw & Co., Inc. 0.82% 861,593 +11% 0.39% $484,447,896
PRICE T ROWE ASSOCIATES INC /MD/ 0.77% 804,910 +5% 0.05% $452,578,000
Legal & General Group Plc 0.73% 770,359 +4.2% 0.1% $433,149,757
CHARLES SCHWAB INVESTMENT MANAGEMENT INC 0.72% 755,565 +4.9% 0.07% $424,831,533
UBS AM, A DISTINCT BUSINESS UNIT OF UBS ASSET MANAGEMENT AMERICAS LLC 0.71% 744,173 -14% 0.09% $418,426,152
AQR CAPITAL MANAGEMENT LLC 0.69% 721,354 +529% 0.26% $405,595,821
DEUTSCHE BANK AG\ 0.66% 696,681 -2% 0.13% $391,722,827

Institutional Holders of REGENERON PHARMACEUTICALS, INC. - COMMON STOCK (REGN) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price Investors
2025 Q4 757,491 $584,646,627 -$27,516,824 $771.87 68
2025 Q3 86,922,112 $48,893,674,176 -$1,217,117,620 $562.27 1,225
2025 Q2 89,209,869 $46,858,212,368 -$1,426,702,161 $525.00 1,192
2025 Q1 91,953,296 $58,281,540,993 -$1,190,545,250 $634.23 1,271
2024 Q4 93,003,966 $66,292,875,044 +$312,411,528 $712.33 1,286
2024 Q3 91,369,529 $95,849,165,939 -$2,790,889,009 $1051.24 1,365
2024 Q2 93,931,197 $98,688,716,978 +$2,504,344,607 $1051.03 1,315
2024 Q1 91,558,421 $88,000,702,452 +$1,166,274,881 $962.49 1,293
2023 Q4 729,638 $641,009,482 -$145,675,694 $878.29 17
2023 Q3 89,932,366 $74,022,797,461 -$573,165,604 $822.96 1,149
2023 Q2 90,747,690 $65,274,231,910 -$2,750,858,930 $718.54 1,138
2023 Q1 90,384,111 $74,219,149,328 -$1,223,946,196 $821.67 1,158
2022 Q4 91,259,426 $65,828,079,390 -$200,302,784 $721.49 1,127
2022 Q3 91,689,090 $63,201,513,150 -$159,913,856 $688.87 1,043
2022 Q2 92,956,330 $54,930,158,972 +$596,089,818 $591.13 1,037
2022 Q1 82,170,454 $57,370,125,075 +$1,529,724,018 $698.42 1,061
2021 Q4 69,921,237 $44,127,182,246 +$441,749,897 $631.52 1,047
2021 Q3 69,491,728 $42,013,552,560 +$478,267,410 $605.18 991
2021 Q2 79,727,291 $44,477,094,257 -$28,924,360 $558.54 947
2021 Q1 89,362,407 $42,245,647,798 -$352,691,727 $473.14 902
2020 Q4 89,468,967 $43,176,601,269 -$836,292,760 $483.11 879
2020 Q3 89,812,777 $50,283,258,601 -$626,633,279 $559.78 888
2020 Q2 90,646,424 $56,512,811,066 +$10,659,071,473 $623.65 912
2020 Q1 73,839,990 $36,044,844,177 +$991,849,560 $488.29 786
2019 Q4 73,130,739 $27,455,902,850 +$184,251,756 $375.48 677
2019 Q3 72,804,983 $20,195,823,274 -$56,972,585 $277.40 603
2019 Q2 73,582,846 $23,022,199,854 +$181,006,352 $313.00 640
2019 Q1 72,413,136 $29,714,550,713 -$48,442,835 $410.62 692
2018 Q4 73,028,151 $27,275,544,609 -$163,089,694 $373.50 648
2018 Q3 73,300,653 $29,613,843,634 +$479,311,958 $404.04 623
2018 Q2 72,229,620 $24,917,010,854 +$363,477,996 $344.99 602
2018 Q1 71,966,803 $24,777,574,861 +$206,772,482 $344.36 601
2017 Q4 71,108,267 $26,733,454,598 -$475,891,788 $375.96 617
2017 Q3 71,864,949 $32,130,149,743 -$383,636,432 $447.12 590
2017 Q2 72,633,782 $35,667,988,549 +$1,276,921,411 $491.14 585
2017 Q1 71,473,047 $27,694,183,545 +$2,456,692,713 $387.51 564
2016 Q4 71,758,870 $26,343,584,723 -$644,622,147 $367.09 564
2016 Q3 72,762,550 $29,238,474,482 +$503,682,119 $402.02 543
2016 Q2 71,618,478 $25,024,959,783 -$370,198,371 $349.23 531
2016 Q1 71,675,066 $25,835,562,007 -$143,426,414 $360.44 536
2015 Q4 72,777,366 $39,508,716,129 -$22,629,662 $542.87 566
2015 Q3 73,042,929 $33,974,644,264 -$196,729,040 $465.14 550
2015 Q2 72,858,532 $37,169,648,718 +$405,385,955 $510.13 531
2015 Q1 72,952,735 $32,932,257,708 +$440,864,535 $451.48 502
2014 Q4 72,035,196 $29,553,171,522 +$117,753,889 $410.25 504
2014 Q3 71,645,929 $25,825,991,495 -$604,937,030 $360.52 470
2014 Q2 73,368,344 $20,726,843,276 -$13,507,747 $282.47 444
2014 Q1 73,402,366 $22,037,080,841 -$740,903,044 $300.28 448